Covid19, Environment, Clinicopathologic Features, Laboratory Findings and Diagnosis, Treatment, Vaccines, Animals, and Cancer

Abstract

SARS-CoV-2 (COVID-19) belongs to the same coronavirus group (Beta-coronavirus) as SARS and MERS viruses that caused two of the more severe epidemics in recent years. Horseshoe bats (genus Rhinolophus) have been identified as the natural reservoirs of SARS-related coronaviruses (CoVs) and the likely origin of SARS-CoV-2. The intermediate host is thought to be the pangolin. The purpose of this review is to draw attention to the relationship between COVID-19 and different malignancies, and to discuss the similarities in their pathogenesis, and the possible repurposing of cancer drugs for the treatment of COVID-19. Along with antiviral and anti-inflammatory drugs, several anti-cancer drugs can be potentially repurposed in the management of COVID-19. The pathogenesis of COVID-19 and cancer shares certain similarities, including inflammation, immunological dysregulation, and coagulopathy. Blood parameters in COVID-19 patients upon admission show lymphocytopenia, and elevated C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH), and D-dimer levels in most of the patients. Currently, RT-PCR is the gold-standard laboratory test for COVID-19 confirmation in suspected cases.

Development of Magnetic-Silica Particles and In-house Buffers Kit for SARS-CoV-2 and CDV RNA Extraction

“…Many methods have been developed for SARS-CoV-2 detection in humans, such as immunological assays based on antibody or antigen detection, gene amplification techniques (polymerase chain reaction (PCR) and isothermal nucleic acid amplification), and novel developed technologies like using biosensors [2][3]. However, molecular diagnostics through gene amplification techniques, especially PCR, still become the golden standard of SARS-CoV-2 detection because it targets the pathogen's genome or proteome, making them more specific, precise, and sensitive [4][5].…”